The chart below shows how ALAB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALAB sees a -1.26% change in stock price 10 days leading up to the earnings, and a +0.30% change 10 days following the report. On the earnings day itself, the stock moves by -1.90%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Record Quarterly Revenue Growth: Astera Labs achieved a record quarterly revenue of $141,100,000 in Q4 2024, representing a 25% increase from the previous quarter and a remarkable 179% increase year-over-year.
Sales Growth Surge: For the full year 2024, Astera Labs reported total sales of $396,000,000, marking a 242% year-over-year growth, driven primarily by the Ares and Torus product families.
Strong Non-GAAP Gross Margin: The company maintained a strong non-GAAP gross margin of 74.1% in Q4, demonstrating effective cost management despite a product mix shift towards hardware solutions.
Workforce Expansion Strategy: Astera Labs successfully increased its workforce by nearly 80% in 2024, reaching a total of 440 full-time employees, which supports its growth strategy and R&D capabilities.
Projected Q1 Revenue Growth: The company anticipates Q1 2025 revenues to rise to between $151,000,000 and $155,000,000, reflecting a projected growth of 7% to 10% from the prior quarter.
Negative
Gross Margin Decline: Non GAAP gross margins decreased to 74.1% in Q4, down from previous levels due to a product mix shift towards hardware-based solutions, indicating potential pressure on profitability.
Rising Operating Expenses: Non GAAP operating expenses rose to $56.2 million in Q4, up from $51.3 million in the previous quarter, reflecting increased spending on R&D and a recent acquisition, which could strain future profitability.
Operating Cash Flow Concerns: Cash flow from operating activities for Q4 was $39.7 million, suggesting potential liquidity concerns as operating expenses continue to rise.
Inventory Surge Analysis: Inventory levels surged nearly 80% sequentially in Q4, reaching an all-time high, which may indicate overproduction or reduced demand expectations going forward.
Q1 Fiscal 2025 Expense Guidance: Guidance for Q1 of fiscal 2025 indicates non GAAP operating expenses are expected to increase to approximately $66 million to $67 million, suggesting ongoing cost pressures despite revenue growth.
Earnings call transcript: Astera Labs Q4 2024 sees strong growth but stock dips
ALAB.O
-3.06%